COVID-19 treatments: research and development
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA is providing guidance to assist developers of potential COVID-19 treatments to prepare for eventual applications for marketing authorisation.
The outcome of any consultation or advice from EMA is not binding on developers.
Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
---|---|---|---|
A64-DP | BCN Peptides SA | Immunomodulator | Non-clinical phase |
Acalabrutinib | Acerta Pharma BV / AstraZeneca | Immunomodulator | Clinical phase |
Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin | Alliance hyperimmune project (Biotest AG, Bio Products Laboratory, LFB, Octapharma, CSL Behring and Takeda) | Antiviral | Clinical phase |
APN01 | Apeiron Biologics | Immunomodulator | Clinical phase |
Apremilast | Amgen Europe BV | Immunomodulator | Clinical phase |
AZD7442 | AstraZeneca | Antiviral (monoclonal antibody) | Non-clinical phase |
Baricitinib | Eli Lilly | Immunomodulator | Clinical phase |
CD24Fc | Oncoimmune Inc | Immunomodulator | Clinical phase |
CHAG-COVID19-CA | ChimAgents | Challenge agent for human infection models | Non-clinical phase |
Chloroquine | Oxford University | Other therapeutic | Clinical phase |
Chloroquine and hydroxychloroquine cyclops DPI | PureIMS | Other therapeutic | Clinical phase |
Copper chloride | ACOM | Antiviral | Clinical phase |
CT-P59 | Celltrion | Antiviral (monoclonal antibody) | Non-clinical phase |
Danoprevir | Ascletis Pharmaceuticals Co Ltd | Antiviral | Clinical phase |
Eculizumab | Alexion | Immunomodulator | Clinical phase |
Emapalumab and anakinra | Swedish Orphan Biovitrum AB (SOBI) | Immunomodulator | Clinical phase |
FAV00B | Farmak International Holding GmbH | Antiviral | Non-clinical phase |
Favipiravir | Glenmark Pharmaceuticals Ltd | Antiviral | Clinical phase |
Gimsilumab | Roivant | Immunomodulator | Clinical phase |
Kamada Anti-SARS-CoV-2 | Kamada Ireland Ltd | Immunoglobulin | Non-clinical phase |
Larifan Plus | Auramed Ltd | Antiviral | Non-clinical phase |
LY-CoV555 (LY3819253) and LY-CoV016 (LY3832479) | Eli Lilly | Antiviral (monoclonal antibody) | Non-clinical phase |
M5049 | Merck Healthcare | Immunomodulator | Non-clinical phase |
Mavrilimumab | Kiniksa Pharmaceuticals | Immunomodulator | Clinical phase |
Meplazumab | Jiangsu Pacific Meinuoke Biopharmaceutical Co Ltd | Antiviral (monoclonal antibody) | Clinical phase |
MK-4482 | Ridgeback Biotherapeutics LP/Merck Sharp & Dohme (Europe) Inc | Antiviral | Non-clinical phase |
Otilimab | GSK | Immunomodulator | Clinical phase |
PF-07304814 | Pfizer | Antiviral | Non-clinical phase |
Raloxifene | Dompé | Antiviral | Non-clinical phase |
Ravulizumab | Alexion | Other therapeutics | Clinical phase |
RBT-9 | Renibus Therapeutics Inc | Antiviral | Clinical phase |
REGN10933, REGN10987, REGN10989 | Regeneron UK | Antiviral (monoclonal antibody) | Non-clinical phase |
Remdesivir | Gilead | Antiviral | Clinical phase |
RESP301 | Thirty Respiratory Limited (30 Technology) | Antiviral | Non-clinical phase |
Sarilumab | Sanofi Aventis | Immunomodulator | Clinical phase |
Siltuximab | EUSApharma | Immunomodulator | Clinical phase |
Tocilizumab | Roche | Immunomodulator | Clinical phase |
UNI911 | Union Therapeutics | Antiviral | Clinical phase |
VIR-7831, VIR-7832 | Vir Biotechnology/GSK | Antiviral (monoclonal antibody) | Clinical phase |
SNG001 | Synairgen Research Limited | Immunomodulator | Clinical phase |
VRP-033 | Venus Pharma GmbH | Immunomodulator | Non-clinical phase |
BRII-196, BRII-198 | Brii Biosciences | Antiviral (monoclonal antibody) | Non-clinical phase |
SCTA01 | Sinocelltech Ltd. | Antiviral (monoclonal antibody) | Clinical phase |
Itolizumab | Biocon Biologics Limited | Immunomodulator | Clinical phase |
BI 764198 | Boehringer Ingelheim International GmbH | Other therapeutic | Clinical phase |
4P021 | 4P-Pharma | Antiviral | Non-clinical phase |
Masitinib mesylate | AB Science | Antiviral | Non-clinical phase |
EX-14870 | Boehringer Ingelheim International BmBH | Antiviral | Non-clinical phase |
2-DEOXY-D-GLUCOSE | Dermin Sp. Z.0.0 | Other therapeutic | Non-clinical Phase Clinical phase |
Emiplacel | Biopharma Excellence GmbH | Other therapeutic | Clinical phase |
AT-527 | Roche | Antiviral | Clinical phase |
ABBV-47D11 | AbbVie | Antiviral | Clinical phase |
Aviptadil | Relief Therapeutics Holding S.A | Other therapeutic | Clinical phase |
AR-711 | Aridis Pharmaceuticals, Inc. | Antiviral (monoclonal antibody) | Non-clinical phase |
Colchicine | Pharmascience Inc. (PMS) / Montreal Health Institute (MHI) | Immunomodulator | Clinical phase |
CoviFab | Inmunova S.A. / mAbxience | Antiviral | Clinical phase |
Trimodulin (human IgM, IgA, IgG solution) | Biotest AG | Immunomodulator | Clinical phase |
MK-7110 | Merck Sharp & Dohme (MSD) / Merck & Co. | Immunomodulator | Clinical phase |
Camostat | Daewoong | Antiviral | Clinical phase |
Bemcentinib | BergenBio | Antiviral | Clinical phase |
Vidofludimus calcium (IMU–838) | Immunic AG | Immunomodulator / Antiviral | Clinical phase |
Vilobelimab | InflaRx GmbH | Immunomodulator | Clinical phase |
FBR-002 | Fab'entech | Antiviral (monoclonal antibody) | Clinical phase |
BMS986414 and BMS986413 | Rockefeller University and Bristol Myers Squibb | Antiviral (monoclonal antibody) | Clinical phase |
Proxalutamide | Suzhou Kintor Pharmaceuticals / Applied Biology | Other therapeutic | Clinical phase |
Calcifediol | Vifor Fresenius Medical Care Renal Pharma France | Other therapeutic | Clinical phase |
Lenzilumab | Humanigen | Immunomodulator | Clinical phase |
Azelastine | Ursapharm | Immunomodulator | Clinical phase |
Opaganib hydrochloride | RedHill Biopharma | Other therapeutic | Clinical phase |
MAD0004J08 | Menarini Ricerche S.p.A. | Antiviral (monoclonal antibody) | Clinical phase |
C21 | Vicore Pharma | Immunomodulator | Clinical phase |
nezulcitinib | Theraevance Biopharma | Immunomodulator | Clinical phase |
Imlifidase (Idefirix) | Hansa Biopharma AB | Immunomodulator | Clinical phase |
WP 1122 | Wpd Pharmaceuticals Sp z o.o | Other therapeutic | Non clinical phase |
RGB-22 | Chemical Works Of Gedeon Richter PLC | Antiviral | Non-clinical phase |
XAV-19 | Xenothera | Antiviral | Clinical phase |
Imatinib Mesilate | Exvastat | Immunomodulator | Clinical phase |
PF-07321332 | Pfizer | Antiviral | Clinical phase |
Fostamatinib | Rigel | Immunomodulator | Clinical phase |
ADG20 | Adagio Therapeutics | Immunomodulator | Clinical phase |
Interferon alfa (INF-alpha), chimeric | Genova Inc | Other therapeutic | Non-clinical phase |
XVR011 | Exevir Bio | Antiviral | Clinical phase |
N,N’-bis[2-(1H-imidazol-2-yl)ethyl]pentanediamide | Treamid GmbH | Immunomodulator | Clinical phase |
S-217622B | Shionogi B.V. | Antiviral | Clinical phase |
CYCLOBENZAPRINE HYDROCHLORIDE | M-Squared Consulting S.r.l. | Other therapeutic | Clinical phase |
F004 | HWI Analytik GmbH | Antiviral | Non-clinical phase |
XC221GI | Valenta Pharmaceuticals JSC | Antiviral | Clinical phase |
RMD-101 | Remedy Biologics Limited | Antiviral | Non-clinical phase |
PRO75 | Evotec International GmbH | Antiviral (monoclonal antibody) | Non-clinical phase |
Reparixin | Dompé farmaceutici s.p.a | Immunomodulator | Clinical phase |
Ensovibep | Novartis | Antiviral | Clinical phase |
Ivermectin | Hwi Pharma Services GmbH | Antiviral | Clinical phase |
HH-120 | Huahui Health Ltd. | Antiviral | Clinical phase |
ASUNERCEPT | Apogenix AG | Immunomodulator | Clinical phase |
Regdanvimab | Celltrion Healthcare Hungary Kft. | Antiviral (monoclonal antibody) | Clinical phase |
Plitidepsin | Pharma Mar, S.A. | Antiviral | Clinical phase |
Ronapreve | Regeneron | Antiviral (monoclonal antibody) | Clinical phase |
Cetylpyridinium chloride | Veristat Spain S.L. | Antiviral | Clinical phase |
Olokizumab | R-Pharm CJSC | Antiviral (monoclonal antibody) | Clinical phase |
Aprotinin | Gerencia De Atención Integrada De Ciudad Real | Antiviral | Clinical phase |
Niclosamide nasal spray | Union Therapeuthics | Antiviral | Clinical phase |
AZD7518 (AZD3152, AZD3959) | AstraZeneca AB | Antiviral (monoclonal antibody) | Clinical phase |
Sabizabulin | Veru Inc. | Antiviral | Clinical phase |
TATX-03 (21-F2, 22-F7, 23-H7, 2-A6) | Talem Therapeutics LLC | Antiviral (monoclonal antibody) | Clinical phase |
GS-5245 | Gilead Sciences Ireland Unlimited Company | Antiviral | Clinical phase |
SPK001 | SpikImm | Antiviral (monoclonal antibody) | Clinical phase |
BC 007 (GS 522 or ARC183) | Berlin Cures | Immunomodulator | Clinical phase |
Arylacenamide | Meletios Therapeutics | Antiviral and immunomodulator | Clinical phase |
MK-7845 | Merck | Antiviral | Non-clinical phase |
Bemnifosbuvir hemisulfate | Atea Pharmaceuticals Inc | Antiviral | Clinical phase |
ALG-097558 | Aligos Belgium BV | Antiviral | Non-clinical phase |
This information should not be read as an endorsement of any medicine
Information on ongoing clinical trials for COVID-19 treatments in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):
Users can find information on:
- phase II to phase IV adult clinical trials for COVID-19 treatments where the investigator sites are in the EEA;
- any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.
Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.
For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see: